ONCAlert | 2018 ASCO Annual Meeting

Genomic Analysis of CALGB 40601 for HER2-Positive Breast Cancer

Maki Tanioka, MD, PhD
Published Online: 3:30 AM, Mon December 12, 2016


Maki Tanioka, MD, PhD, a postdoctoral research associate at UNC Lineberger Comprehensive Cancer Center, discusses an integrated analysis of multidimensional genomic data on the phase III CALGB 40601 (Alliance) study, which explored neoadjuvant weekly paclitaxel and trastuzumab (Herceptin) with or without lapatinib for patients with HER2-positive breast cancer,

Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.